Gabelli has reiterated Greatbatch Inc's GB Buy Rating in a recent report.
According to Gabelli, “At the company's March 24 investor day, Greatbatch provided insight into ten cardiovascular and neurostimulation projects, the first three of which have gained regulatory approval and are starting to accelerate sales growth and improve margins. As the remaining seven projects gain approval over the next three years,
Greatbatch can accelerate sales growth from 2% towards 7% and increase operating margins from the current 12% to 16%. With this growth and continuing debt paydown, Greatbatch can grow earnings at a 15% rate. We continue to recommend that investors purchase Greatbatch shares.”
GB has a Buy Rating and closed yesterday at $26.07 a share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in